Singh Lab

Publications

Singh, K; Le, H; Marasini, B; Xiao, P; Villinger, F; O’Donnell, KL; Marzi, A; Spearman, P. Pre-clinical evaluation of immunogenicity and protective efficacy of a pan-orthoebolavirus virus-like particle (VLP) vaccine 3075. Journal of Immunology. 2025; 214(Supplement_1).

Spearman, P; Jin, H; Xiao, P; Knopp, K; Radziewicz, H; Tellier, M; Larsen, SE; Berube, BJ; Song, X; Kidd, J; Falsey, AR; Coler, R; Villinger, FJ; He, B. Safety and immunogenicity of intranasal parainfluenza virus type 5 (PIV5)-vectored COVID-19 vaccine in adults and teens in an open-label phase 1 trial. Science Advances. 2025; 11(27):eadw0896.

Rostad, CA; Yildirim, I; Kao, C; Yi, J; Kamidani, S; Peters, E; Stephens, K; Gibson, T; Hsiao, H-M; Singh, K; Wrammert, J; Suthar, M; Rouphael, N; Anderson, EJ. A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose. npj Vaccines. 2024; 9(1):255.

Spearman, P; Jin, H; Knopp, K; Xiao, P; Gingerich, MC; Kidd, J; Singh, K; Tellier, M; Radziewicz, H; Wu, S; Wang, Z; John, SP; Villinger, FJ; He, B. Intranasal parainfluenza virus type 5 (PIV5)-vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study. Science Advances. 2023; 9(43):eadj7611.

Singh, K; Le, H. Ebola virus protein VP40 induces accessory cell-mediated activation of human natural killer (NK) cells. Journal of Immunology. 2023; 210(Supplement_1):71.33-71.33.

Le, H; Spearman, P; Waggoner, SN; Singh, K. Ebola virus protein VP40 stimulates IL-12- and IL-18-dependent activation of human natural killer cells. JCI Insight. 2022; 7(16).

Xiao, P; Dienger-Stambaugh, K; Chen, X; Wei, H; Phan, S; Beavis, AC; Singh, K; Adhikary, NRD; Tiwari, P; Villinger, F; He, B; Spearman, P. Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates. Frontiers in Immunology. 2021; 12:623996.